AQR Capital Management’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $858K | Buy |
933,098
+513,545
| +122% | +$622K | ﹤0.01% | 2861 |
|
|
2025
Q4 | $537K | Sell |
419,553
-68,546
| -14% | -$92.1K | ﹤0.01% | 2872 |
|
|
2025
Q3 | $635K | Sell |
488,099
-123,964
| -20% | -$162K | ﹤0.01% | 2685 |
|
|
2025
Q2 | $734K | Buy |
612,063
+129,151
| +27% | +$143K | ﹤0.01% | 2389 |
|
|
2025
Q1 | $522K | Buy |
482,912
+432,725
| +862% | +$608K | ﹤0.01% | 2407 |
|
|
2024
Q4 | $87.8K | Sell |
50,187
-36,987
| -42% | -$68.9K | ﹤0.01% | 2778 |
|
|
2024
Q3 | $168K | Sell |
87,174
-156,063
| -64% | -$306K | ﹤0.01% | 2598 |
|
|
2024
Q2 | $431K | Buy |
243,237
+179,817
| +284% | +$440K | ﹤0.01% | 2117 |
|
|
2024
Q1 | $172K | Buy |
+63,420
| New | +$153K | ﹤0.01% | 2277 |
|
|
2021
Q4 | – | Sell |
-52,952
| Closed | -$349K | – | 2240 |
|
|
2021
Q3 | $349K | Buy |
52,952
+15,967
| +43% | +$105K | ﹤0.01% | 1995 |
|
|
2021
Q2 | $228K | Sell |
36,985
-161,162
| -81% | -$862K | ﹤0.01% | 2114 |
|
|
2021
Q1 | $896K | Sell |
198,147
-121,031
| -38% | -$665K | ﹤0.01% | 1598 |
|
|
2020
Q4 | $1.92M | Buy |
319,178
+156,142
| +96% | +$1.03M | ﹤0.01% | 1185 |
|
|
2020
Q3 | $1.21M | Sell |
163,036
-124,874
| -43% | -$862K | ﹤0.01% | 1324 |
|
|
2020
Q2 | $1.16M | Buy |
287,910
+40,267
| +16% | +$140K | ﹤0.01% | 1405 |
|
|
2020
Q1 | $629K | Buy |
247,643
+57,845
| +30% | +$190K | ﹤0.01% | 1504 |
|
|
2019
Q4 | $660K | Sell |
189,798
-74,650
| -28% | -$263K | ﹤0.01% | 1664 |
|
|
2019
Q3 | $1.22M | Sell |
264,448
-66,008
| -20% | -$520K | ﹤0.01% | 1468 |
|
|
2019
Q2 | $4.07M | Buy |
330,456
+115,156
| +53% | +$1.47M | ﹤0.01% | 1033 |
|
|
2019
Q1 | $2.86M | Buy |
215,300
+190,189
| +757% | +$2M | ﹤0.01% | 1190 |
|
|
2018
Q4 | $216K | Buy |
+25,111
| New | +$196K | ﹤0.01% | 2054 |
|
|
2017
Q1 | – | Sell |
-16,367
| Closed | -$119K | – | 2219 |
|
|
2016
Q4 | $119K | Buy |
+16,367
| New | +$103K | ﹤0.01% | 2202 |
|
|
2016
Q3 | – | Sell |
-25,187
| Closed | -$227K | – | 2273 |
|
|
2016
Q2 | $227K | Buy |
25,187
+9,324
| +59% | +$87.6K | ﹤0.01% | 2082 |
|
|
2016
Q1 | $128K | Buy |
+15,863
| New | +$114K | ﹤0.01% | 2160 |
|
|
2015
Q1 | – | Sell |
-8,770
| Closed | -$296K | – | 2226 |
|
|
2014
Q4 | $296K | Sell |
8,770
-24,000
| -73% | -$680K | ﹤0.01% | 2212 |
|
|
2014
Q3 | $803K | Sell |
32,770
-3,500
| -10% | -$98.4K | ﹤0.01% | 1725 |
|
|
2014
Q2 | $1.07M | Buy |
36,270
+400
| +1% | +$12.8K | ﹤0.01% | 1614 |
|
|
2014
Q1 | $1.58M | Buy |
35,870
+26,300
| +275% | +$1.16M | ﹤0.01% | 1443 |
|
|
2013
Q4 | $367K | Buy |
+9,570
| New | +$282K | ﹤0.01% | 2214 |
|
Other funds holding LAB
CC
MCO
LFCM
VCM
HBWM
AQR Capital Management's LAB Position: Q1 2026 in Review
AQR Capital Management increased its Standard BioTools (LAB) stake by 122% in Q1 2026, buying an estimated $622K and bringing the position to 933,098 shares worth $858K. The position accounts for ﹤0.01% of the portfolio, ranked #2861.
AQR Capital Management first reported a position in LAB in Q4 2013 and has held it in 29 quarters since. The position peaked at $4.07M in Q2 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.
- AQR Capital Management held 933,098 shares of Standard BioTools worth $858K as of Q1 2026.
- AQR Capital Management bought 513,545 Standard BioTools shares in Q1 2026, an estimated $622K.
- Standard BioTools made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2861 holding.
- AQR Capital Management first reported a position in Standard BioTools in Q4 2013 and has held it in 29 quarters since.
- AQR Capital Management's Standard BioTools position peaked at $4.07M in Q2 2019.
- 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.
Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.